{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Expressing+Solid+Tumours",
    "query": {
      "condition": "HER2 Expressing Solid Tumours"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 34,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Expressing+Solid+Tumours&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T14:44:38.365Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01730118",
      "title": "Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Breast Cancer",
        "Adenocarcinomas",
        "Metastatic Solid Tumors Characterized by HER2/Neu Expression"
      ],
      "interventions": [
        {
          "name": "Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2013-03-04",
      "completion_date": "2019-12-03",
      "has_results": true,
      "last_update_posted_date": "2022-09-10",
      "last_synced_at": "2026-06-25T14:44:38.365Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01730118"
    },
    {
      "nct_id": "NCT02840110",
      "title": "Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "B Cell Lymphomas",
        "Multiple Myeloma",
        "Solid Tumor",
        "HER-2 Protein Overexpression"
      ],
      "interventions": [
        {
          "name": "ACTR T Cell Product",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Cogent Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2016-10",
      "completion_date": "2021-02-23",
      "has_results": false,
      "last_update_posted_date": "2021-10-11",
      "last_synced_at": "2026-06-25T14:44:38.365Z",
      "location_count": 16,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • New Haven, Connecticut + 13 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02840110"
    },
    {
      "nct_id": "NCT04278144",
      "title": "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HER2-positive Solid Tumors",
        "HER2-positive Breast Cancer",
        "HER2-positive Colorectal Cancer",
        "HER2-positive Gastroesophageal Cancer",
        "HER2-positive Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "BDC-1001",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bolt Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2020-02-24",
      "completion_date": "2025-02-14",
      "has_results": false,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-06-25T14:44:38.365Z",
      "location_count": 11,
      "location_summary": "Palo Alto, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04278144"
    },
    {
      "nct_id": "NCT07192432",
      "title": "Gene Therapy for HER-Positive Cancer (SENTRY-HER2)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HER2 Expressing Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Dose Level 1, VNX-202",
          "type": "GENETIC"
        },
        {
          "name": "Dose Level 2, VNX-202",
          "type": "GENETIC"
        },
        {
          "name": "Dose Level 3, VNX-202",
          "type": "GENETIC"
        },
        {
          "name": "Dose Level 4, VNX-202",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Vironexis Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2025-11-18",
      "completion_date": "2033-10",
      "has_results": false,
      "last_update_posted_date": "2026-06-24",
      "last_synced_at": "2026-06-25T14:44:38.365Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07192432"
    },
    {
      "nct_id": "NCT07228247",
      "title": "A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors, Adult"
      ],
      "interventions": [
        {
          "name": "HMPL-A251",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchmed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 147,
      "start_date": "2025-12-16",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-06-25T14:44:38.365Z",
      "location_count": 9,
      "location_summary": "Denver, Colorado • Plantation, Florida • Tamarac, Florida + 5 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "East Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07228247"
    },
    {
      "nct_id": "NCT05013554",
      "title": "Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasm Malignant",
        "Breast Cancer",
        "Lung Neoplasm Malignant",
        "Gastric Cancer",
        "Neoplasm"
      ],
      "interventions": [
        {
          "name": "SAR443216 IV",
          "type": "DRUG"
        },
        {
          "name": "SAR443216 SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2021-08-16",
      "completion_date": "2024-01-15",
      "has_results": false,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-06-25T14:44:38.365Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05013554"
    },
    {
      "nct_id": "NCT06254807",
      "title": "CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive"
      ],
      "interventions": [
        {
          "name": "CT-0525",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Carisma Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2024-01-08",
      "completion_date": "2026-03-31",
      "has_results": false,
      "last_update_posted_date": "2024-12-19",
      "last_synced_at": "2026-06-25T14:44:38.365Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06254807"
    },
    {
      "nct_id": "NCT04585958",
      "title": "Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Malignant Solid Neoplasm",
        "Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma",
        "Unresectable Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2021-05-21",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-06-25T14:44:38.365Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04585958"
    },
    {
      "nct_id": "NCT02829372",
      "title": "Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2 Expressing Solid Tumours"
      ],
      "interventions": [
        {
          "name": "CD3/HER2 bispecific monoclonal antibody",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ichnos Sciences SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2016-05",
      "completion_date": "2019-05",
      "has_results": false,
      "last_update_posted_date": "2020-10-09",
      "last_synced_at": "2026-06-25T14:44:38.365Z",
      "location_count": 4,
      "location_summary": "Fairway, Kansas • Detroit, Michigan • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02829372"
    },
    {
      "nct_id": "NCT04460456",
      "title": "A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2 Positive Solid Tumors"
      ],
      "interventions": [
        {
          "name": "SBT6050",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Silverback Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2020-07-27",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2022-06-30",
      "last_synced_at": "2026-06-25T14:44:38.365Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Durham, North Carolina • Pittsburgh, Pennsylvania + 3 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04460456"
    }
  ]
}